Parity, infertility, oral contraceptives, and hormone replacement therapy and the risk of ovarian serous borderline tumors: A nationwide case-control study

Emma L.Kaderly Rasmussen, Charlotte Gerd Hannibal, Christian Dehlendorff, Louise Baandrup, Jette Junge, Russell Vang, Robert J. Kurman, Susanne K. Kjaer

Research output: Contribution to journalArticlepeer-review

Abstract

Objective Few studies have examined the risk of an ovarian serous borderline tumor (SBT) associated with parity, infertility, oral contraceptives (OCs), or hormone replacement therapy (HRT), which was the study aim. Methods This nationwide case-control study included all women with an SBT diagnosis in Denmark, 1978–2002. SBTs were confirmed by centralized expert pathology review. For each case, 15 age-matched female controls were randomly selected using risk-set sampling. Cases and controls with previous cancer (except for non-melanoma skin cancer) and controls with bilateral oophorectomy or salpingo-oophorectomy were excluded. Conditional logistic regression was used to estimate adjusted odds ratios (ORs) and 95% confidence intervals (CIs). Results We found a strongly decreased risk of SBTs among parous women which decreased with increasing number of children (p < 0.01). Older age at first birth also decreased the SBT risk (p = 0.03). An increased SBT risk was associated with infertility (OR = 3.31; 95% CI: 2.44–4.49), which was present both among parous and nulliparous women. HRT use increased the SBT risk (OR = 1.32; 95% CI: 1.02–1.72), whereas OC use decreased the risk (OR = 0.40; 95% CI: 0.26–0.62). Conclusions Our nationwide study with expert histopathologic review of all SBTs showed that parity, infertility, use of HRT, and use of OCs, respectively, were strongly associated with the risk of SBTs. This is the first study to report a strong and significantly decreased SBT risk associated with OC use and a significantly increased risk with infertility, and HRT use. This supports that SBTs and serous ovarian cancer share similar risk factors.

Original languageEnglish (US)
Pages (from-to)571-576
Number of pages6
JournalGynecologic oncology
Volume144
Issue number3
DOIs
StatePublished - Mar 1 2017

Keywords

  • Hormone replacement therapy (HRT)
  • Infertility
  • Oral contraceptive (OC)
  • Ovarian serous borderline tumor (SBT)
  • Parity
  • Risk factor

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'Parity, infertility, oral contraceptives, and hormone replacement therapy and the risk of ovarian serous borderline tumors: A nationwide case-control study'. Together they form a unique fingerprint.

Cite this